Log in

Relevant bibliographies by topics / Somatostatine, analogue

Contents

Journal articles

Academic literature on the topic 'Somatostatine, analogue'

Author: Grafiati

Published: 4 June 2021

Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Somatostatine, analogue.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Somatostatine, analogue"

1

Azzoug, S., F. Chentli, and K. Chaou. "Fistule pancréatique traitée par analogue de la somatostatine." Annales d'Endocrinologie 75, no. 5-6 (2014): 363. http://dx.doi.org/10.1016/j.ando.2014.07.311.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Marjanovic, Vesna, Andjelka Slavkovic, Miroslav Stojanovic, Vladisav Stefanovic, Goran Marjanovic, and Radmilo Jankovic. "Somatostatine analogue in nonoperative treatment of posttraumatic pancreatic pseudocyst in a child: a case report." Open Medicine 7, no. 1 (2012): 34–37. http://dx.doi.org/10.2478/s11536-011-0108-z.

Full text

Abstract:

AbstractPancreatic pseudocyst is a complication of pancreatic trauma. We describe improved nonoperative treatment of patient with posttraumatic pancreatic pseudocyst with somatostatin analogue. A 9-year-old girl was admitted to our hospital after blunt abdominal trauma with handlebar. Three weeks after abdominal trauma, pancreatic pseudocyst developed. Nonoperative treatment of posttraumatic pancreatic pseudocyst (the largest dimensions 70 × 55 × 65 mm) with somatostatin analogue, octreotide acetate, was applied for the next 52 days. The patient was followed up for 24 months after the discontinuation of octreotide and there were no recurrence of pancreatic pseudocyst. Somatostatin analogue could be usefull in the nonoperative treatment of posttraumatic pancreatic pseudocysts in children.

APA, Harvard, Vancouver, ISO, and other styles

3

Huc, M. Cl, P. Moreau, B. Roullet, et al. "Vipome: échec du traitement par analogue retard de la somatostatine." La Revue de Médecine Interne 12, no. 6 (1991): S452. http://dx.doi.org/10.1016/s0248-8663(05)80796-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Papierska, Lucyna, Jarosław B. Ćwikła, Waldemar Misiorowski, Michał Rabijewski, Krzysztof Sikora, and Hubert Wanyura. "FGF23 Producing Mesenchymal Tumor." Case Reports in Endocrinology 2014 (2014): 1–4. http://dx.doi.org/10.1155/2014/492789.

Full text

Abstract:

A 40-year-old patient was referred to Clinic of Endocrinology due to hypophosphatemia causing pain, cramps, and weakness of muscles. Moreover, his bone mineral density was very low. The previous treatment with phosphorus and active vitamin D metabolites was ineffective. In lab tests the hypophosphatemia, hyperphosphaturia, and elevated FGF23 levels were found. Somatostatin receptor scintigraphy (SRS) showed increased radiotracer uptake in the right maxillary sinus and CT scans confirmed presence of tumor in this localization. Biopsy and cytological examination created suspicion of mesenchymal tumor—glomangiopericytoma. Waiting for surgery the patient was treated with long acting Somatostatine analogue, and directly before operation short acting Octreotide and intravenous phosphorus were used. Histology confirmed the cytological diagnosis and the phosphatemia return to normal values in 10 days after the tumor removal.

APA, Harvard, Vancouver, ISO, and other styles

5

Askaoui, S., G. El Mghari, and N. El Ansari. "Apoplexie hypophysaire sous analogue de la somatostatine : à propos d’un cas." Annales d'Endocrinologie 79, no. 4 (2018): 342. http://dx.doi.org/10.1016/j.ando.2018.06.450.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Butera, Alfredo. "Long lasting octreotide LAR therapy in large cell neuroendocrine carcinoma (LCNEC) of the lung." Clinical Management Issues 4, no. 1S (2015): 15–18. http://dx.doi.org/10.7175/cmi.v4i1s.1066.

Full text

Abstract:

In this article we report a case of a patient with large cell neuroendocrine carcinoma (LCNEC) of the lung. Patients with LCNEC usually have poor prognosis and the benefit of adjuvant chemotherapy for these patients has not been fully established. This case suggests that octreotide LAR, a somatostatine analogue (SSA), can be useful in the treatment of neuroendocrine carcinoma also as maintenance therapy in association with chemotherapy. Further studies, regarding individual tumour biological behaviour and SSAs optimal dosage, could be useful to optimise treatment and to add new insights into the mechanisms of action and the role of SSAs in the therapy of NETs.

APA, Harvard, Vancouver, ISO, and other styles

7

Borie, R. "Le SOM230, un analogue de la somatostatine, inhibe le développement de la fibrose pulmonaire induite par la bléomycine chez la souris." Revue des Maladies Respiratoires 22, no. 6 (2005): 1078. http://dx.doi.org/10.1016/s0761-8425(05)85752-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Borie, R., A. Fabre, J. Marchal, P. Soler, and B. Crestani. "Le SOM230, un analogue de la somatostatine, inhibe le développement de la fibrose pulmonaire induite par la bléomycine chez la souris." Revue des Maladies Respiratoires 23 (January 2006): 108. http://dx.doi.org/10.1016/s0761-8425(06)72412-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Leccia, M. T., M. Fakiha, J. P. Vuillez, G. Bettega, and J. Lebeau. "Régression complète d’une tumeur à cellules de Merckel métastatique par traitement par un analogue de la somatostatine : à propos d’un cas." Annales de Dermatologie et de Vénéréologie 138, no. 12 (2011): A220. http://dx.doi.org/10.1016/j.annder.2011.10.232.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Öberg, Kjell, and Steven W. J. Lamberts. "Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future." Endocrine-Related Cancer 23, no. 12 (2016): R551—R566. http://dx.doi.org/10.1530/erc-16-0151.

Full text

Abstract:

Acromegaly is a hormonal disorder that arises when the pituitary gland secretes excess growth hormone (GH), which in turn stimulates a concomitant increase in serum insulin-like growth factor 1 (IGF-1) levels. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) constitute a heterogeneous group of tumours that can secrete serotonin and a variety of peptide hormones that may cause characteristic symptoms known as carcinoid syndrome or other symptoms and hormonal hypersecretion syndromes depending on the tumour’s site of origin. Current medical therapy for the treatment of acromegaly and GEP-NET involves the administration of somatostatin analogues that effectively suppress excess hormone secretion. After its discovery in 1979, octreotide became the first synthetic biologically stable somatostatin analogue with a short-acting formulation of octreotide introduced into clinical practice in the late 1980s. Lanreotide, another somatostatin analogue, became available in the mid-1990s initially as a prolonged-release formulation administered every 10 or 14 days. Long-acting release formulations of both octreotide (Sandostatin LAR and Novartis) and lanreotide (Somatuline Autogel, Ipsen), based on microparticle and nanoparticle drug-delivery technologies, respectively, were later developed, which allowed for once-monthly administration and improved convenience. First-generation somatostatin analogues remain one of the cornerstones of medical therapy in the management of pituitary and GEP-NET hormone hypersecretion, with octreotide having the longest established efficacy and safety profile of the somatostatin analogue class. More recently, pasireotide (Signifor), a next-generation multireceptor-targeted somatostatin analogue, has emerged as an alternative therapeutic option for the treatment of acromegaly. This review summarizes the development and clinical success of somatostatin analogues.

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!